Avertissement: Ce site agrège des données publiques officielles provenant de la FDA, ClinicalTrials.gov, PubMed et SEC EDGAR à titre de référence générale uniquement. Il ne constitue pas un avis médical, un diagnostic, une recommandation de traitement ni un conseil en investissement.

Essai clinique

Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome

NCT : NCT03325959 · COMPLETED

ID NCTNCT03325959
StatutCOMPLETED
Date de début2017-03-01
Achèvement2022-06-01

Résumé succinct

The investigators have previously studied the efficacy of hyperbaric oxygen therapy (HBOT) as a treatment for Fibromyalgia syndrome (FMS) in a prospective, active control, crossover clinical trial. The results demonstrated significant amelioration of all FMS symptoms, with significant improvement in life quality; furthermore, the investigators were able to demonstrate significant neuroplasticity on SPECT imaging, with a decrease of the hyperactivity in posterior regions and elevation of the reduced activity in frontal areas. In the proposed study, the investigators intend to both repeat and expand our previous findings, treating FMS patients with HBOT while performing an extensive of evaluation both before and after treatment. In the current study, the investigators plan to compare HBOT to current standard of care of FMS (pharmacological and non - pharmacological).

Source officielle

Voir sur ClinicalTrials.gov →

Données issues de l’API ClinicalTrials.gov. Pour connaître le statut le plus récent, consultez la fiche officielle.

↑